RT Journal Article
SR Electronic
T1 CD133 Expression Predicts Relapse in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemotherapy
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 437
OP 445
DO 10.21873/invivo.12276
VO 35
IS 1
A1 HARUKA OI
A1 TAKASHI OKUYAMA
A1 SHUNYA MIYAZAKI
A1 YUKO ONO
A1 MASATOSHI OYA
YR 2021
UL http://iv.iiarjournals.org/content/35/1/437.abstract
AB Aim: The aim of the present study was to explore the association between CD133 expression and postoperative relapses in patients with locally advanced rectal cancer (LARC) who received neoadjuvant chemotherapy (NAC). Patients and Methods: We retrospectively examined 52 patients with LARC (cT3-4, Nany, M0) who received oxaliplatin-based NAC before surgery. CD133 expression was evaluated using immunohistochemistry and divided into low and high expression groups. Results: High CD133 expression was observed in 22 patients (42.3%). Patients with high CD133 expression had more frequent vessel invasion and relapse than those with low CD133 expression (p=0.013 and p=0.036, respectively). Comparing the low with high CD133 expression groups, the 4-year relapse-free survival rates were 82.2% vs. 46.3% (p=0.009). Multivariate analysis indicated that CD133 expression was an independent risk factor for relapse (HR=3.138; 95%CI=1.046-9.412; p=0.041). Conclusion: CD133 expression may be a predictive biomarker for postoperative relapse in patients with LARC who received NAC before surgery.